Tiziana Life Sciences Ltd - Common Shares (TLSA) Covered Calls
You can sell covered calls on Tiziana Life Sciences Ltd - Common Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TLSA (prices last updated Mon 4:16 PM ET):
| Tiziana Life Sciences Ltd - Common Shares (TLSA) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 0.75 | +0.09 | 0.72 | 0.76 | 540K | - | 0.1 |
| Covered Calls For Tiziana Life Sciences Ltd - Common Shares (TLSA) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 17 | 2.5 | 0.00 | 0.76 | 0.0% | 0.0% | |
| Jun 21 | 2.5 | 0.05 | 0.71 | 7.0% | 41.9% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
| Top 10 Open Interest For May 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SPY covered calls | 6. | KWEB covered calls | 1. | CVNA covered calls | |
| 2. | IWM covered calls | 7. | EEM covered calls | 2. | FSLY covered calls | |
| 3. | HYG covered calls | 8. | TSLA covered calls | 3. | PENN covered calls | |
| 4. | QQQ covered calls | 9. | SLV covered calls | 4. | SNAP covered calls | |
| 5. | FXI covered calls | 10. | NVDA covered calls | 5. | CLSK covered calls | |
Want more examples? TLRY Covered Calls | TLT Covered Calls
